Form 4: PMV Pharmaceuticals Chief Development Officer Sells Shares for Tax Obligations
Insider Transaction Report
Deepika Jalota, Chief Development Officer of PMV Pharmaceuticals, sold 33,065 shares of common stock on July 1, 2025, to cover tax obligations related to restricted stock unit vesting.
Summary
- Deepika Jalota, Chief Development Officer of PMV Pharmaceuticals, Inc. (PMVP), sold 33,065 shares of common stock.
- The transaction occurred on July 1, 2025, at a price of $1.0645 per share.
- The sale was conducted to satisfy tax obligations arising from the vesting of restricted stock units (RSUs).
- Following the transaction, Deepika Jalota beneficially owns 89,959 shares of PMV Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: The transaction is a routine sale of shares to cover tax obligations related to RSU vesting, which is a common practice for executives and does not inherently indicate positive or negative sentiment regarding the company's performance or outlook.
Future Outlook
NA
Industry Context
NA
Key Dates
| Date | Description |
|---|---|
| 07/01/2025 | Date of transaction (sale of common stock by Deepika Jalota). |
| 07/03/2025 | Date the Form 4 filing was signed. |
Keywords
PMV Pharmaceuticals, PMVP, Deepika Jalota, Form 4, insider trading, stock sale, restricted stock units, RSU, tax obligations, Chief Development Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.